Shoppers Drug Mart partners with Avicanna to transition Medical Cannabis by Shoppers
Symposium seeks to bring Key Opinion Leaders and health care providers to explore cannabinoid-based R&D, medicine, and clinical adoption from the MaRS Discovery District, Toronto

TORONTO, February 29, 2024 (GLOBE NEWSWIRE) – Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that the Company will host a medical symposium entitled “Cannabinoid-based Medicine in the Canadian Healthcare System – From Emerging Evidence to Clinical Practice” at the MaRS Discovery District, Toronto, Monday, May 13, 2024.

The symposium, with registration limited to health care practitioners and researchers, will cover a range of topics including emerging evidence and practical clinical applications of cannabinoid-based medicine The event will feature key opinion leaders, clinicians, researchers, and scientists from various academic, research and clinical organizations and hospitals and industry. Speakers include:

Dr. Camila Sofia Arriagada Egnen                                                       Dr. Karolina Urban

SickKids, The Hospital for Sick Children                                              Avicanna Inc.

Dr. Alan Bell                                                                                             Samantha Aitken, RPh

University of Toronto                                                                      

Dr. Hance Clarke                                                                                     Aras Azadian

Toronto General Hospital                                                                        Avicanna Inc.

University Health Network

Dr. Carlo DeAngelis                                                                               Andrew Bevan

Sunnybrook Health Sciences Centre                                                    Spectrum Therapeutics

 Dr. Tania Di Renna                                                                                 Erin Prosk

Womens’ College Hospital                                                                      Sante Cannabis

Dr. Julia Hoeng                                                                                        Keith Stratchan

Vectura Fertin Pharma                                                                            MediPharm Labs Corp.

Dr. Evan Lewis

Neurology Centre of Toronto

The event will also highlight necessary education and resources for Health Care Providers seeking to implement medical cannabis as a potential treatment option including the Company’s Avicenna Academy. Avicanna’s team will also be presenting advancements in cannabinoid-based research including the Company’s recently completed research studies in addition to introducing to the medical cannabis care platform.  

“We feel privileged to bring together clinicians and thought leaders with direct experience in prescribing cannabinoid-based medicine and medical cannabis to patients. Our aim is to increase discussion and further explore possibilities around cannabinoid-based medicine’s potential as a treatment option for HCPs” stated Dr. Karolina Urban, Executive Vice President of Medical Affairs at Avicanna. 

To register for the symposium: 

Health care practitioners and researchers, may apply for registration at: 

About Avicanna Inc. 

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across various market segments: 

SOURCE Avicanna Inc. 

Stay Connected 

For more information about Avicanna, visit our website, contact Ivana Maric by email at or follow us on social media on LinkedIn, Twitter, Facebook,or Instagram

The Company posts updates through videos from the Company YouTube channel. 

Cautionary Note Regarding Forward-Looking Information and Statements 

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified using words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated March 31, 2023 filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.